The total deal value shows just how important the Cambridge Cluster still is worldwide, with lots of mergers and acquisitions happening alongside a big boost in investment for Deep Tech and new therapies.
Two deals really stood out because of their size. The largest one was Honeywell buying Johnson Matthey’s catalyst business for about $2.4bn in May. This sale lets Johnson Matthey concentrate on its clean air and Platinum Group Metals (PGMs) divisions.
In life sciences, Astra Zeneca made a key acquisition by snapping up Belgian company Eso Biotec for $425 million upfront, which could reach $1bn if certain goals are met. Eso Biotec’s ENa BL cell therapy platform will help speed up AZ’s plans to develop groundbreaking cancer treatments.
Astra Zeneca, which recently promised to invest $50bn over the next five years in the US, is already moving forward with those plans. Just last week they revealed a $4.5 billion investment in a new factory near Charlottesville, Virginia, starting work immediately. Then this week AZ showed off an upgraded manufacturing site in Coppell, Texas that cost $445m.
Other big M&A moves included UK financial services comparison leader Go. Compare buying Cambridge insurance startup Rnwl for up to £63m, while natural extracts company Treatt agreed to sell for £173.8m to Natara Global.
Photograph courtesy – CMR Surgical.
A surge in funding led by quantum computing and medical robotics
The total disclosed funding raised by Cambridge science and tech firms so far this year has passed $1.697bn. Almost half of that comes from Quantinuum and CMR Surgical, showing strong investor belief in cutting-edge tech.
Quantinuum landed the biggest single raise: $600m at a pre-money valuation of $10bn. Backers like Honeywell, NVIDIA’s NVentures VC arm, and JPMorgan Chase supported the quantum computing leader as it pushes ahead with its Helios system and fault-tolerant computing development.
CMR Surgical brought in another $200m through equity and debt to push global growth of its Versius Surgical Robot System – especially focusing on breaking into the US market.
A few other tech startups also pulled impressive rounds: AI materials search engine Cusp AI raised over $100m Series A; legal AI pioneer Luminance closed a $75m Series C; graphene chip maker Paragraf got an extra $55m funding round.
The life sciences sector keeps drawing international cash
This year so far Cambridge life sciences companies have raised about $734.26m globally for breakthrough therapies. Three firms make up more than half that sum – CMR Surgical ($200m), Cell Centric ($120m), and Charm Therapeutics ($80m).
This May Cell Centric scored a big $120m Series C round to continue fighting a tough form of cancer. They’ll use it mainly to push forward their oral p300/CBP inhibitor drug called inobrodib into registration trials.
The round was co-led by Boston’s RA Capital Management along with newcomer Forbion from the Netherlands plus US investors Avego Bioscience Capital and Bright Edge – which is linked to the American Cancer Society’s venture arm.
The previous month CHARM Therapeutics announced an $80m Series B round aimed at developing top-tier menin inhibitors targeting Acute Myeloid Leukemia (AML). New backers NEA (New Enterprise Associates) and SR One joined existing supporters Orbi Med, F-Prime, NVIDIA, and Khosla Ventures for this raise.
Basing themselves locally at Babraham Research Campus now after raising over $150 million total so far CHARM is pushing its lead menin inhibitor towards early 2026 clinical trials.
This year also saw significant raises from Maxion Therapeutics ($72m), Quibim ($50m), Cyted Health ($44m), Alchemab Therapeutics ($32m), TRIMTECH Therapeutics ($31m) and Owlstone Medical ($27m).
This March Maxion closed an oversubscribed Series A worth £58 million (~$72 million) led by General Catalyst with fresh input from British Patient Capital (part of British Business Bank), Solasta Ventures plus pharma giant Eli Lilly & Company alongside repeat investors Life Arc Ventures, Monograph Capital & BGF. Maxion develops antibody-based Knot Body® drugs aimed at ion channel & GPCR-driven diseases.
Kicking off 2025 Health Tech firm Quibim raised a solid $50 million Series A aiming to transform precision medicine via AI-powered biomarkers technology.
Their round was headed by Asabys through fund Sabadell Asabys II together with Buenavista Equity Partners’ BHG I fund built alongside Columbus Venture Partners; other newcomers were UI Investissement & Go Hub Ventures joining returning backers Amadeus Capital Partners, APEX Ventures & others including Tony Fadell’s Build Collective as well as biotech entrepreneur Dr Jonathan Milner himself.
Cyted Health partnered with Alchemab last month announcing major scale-up financings too – Cyted secured a 44-million-dollar Series B injection focused on expanding within U. S., where it already operates using advanced gastrointestinal molecular diagnostic technologies!
EQT Life Sciences led this latest Cyted round through EQT Health Economics strategy while Advent Life Sciences & British Business Bank co-led; current investors Morningside & BGF stayed involved too.
Photograph courtesy – TRIMTECH Therapeutics.$32M more came into Alchemab Therapeutics lifting their series A haul beyond 114 million dollars altogether! Ono Venture Investment joined forces here along other specialized funds such as RA Capital plus SV Health Investors among others including strategic support from Lilly itself.
Lilly also put money behind TRIMTECH Therapeutics – young Cambridge biotech working on targeted protein degradation strategies against neurodegenerative disorders. TRIMTECH secured an oversubscribed £25 million seed earlier this year involving numerous US-based investors.
CIC (Cambridge Innovation Capital) led that raise along SV Health Investors Dementia Discovery Fund plus M Ventures USA & Pfizer Ventures NYC all participating alongside Eli Lilly Co., MP Healthcare Venture Management USA plus local players like Cambridge Enterprise Ventures + Start Codon (now part of CIC family).
Basing itself outta Cambridge Owlstone Medical kept busy starting 2025 w/$27M first close on their series E financing lead by Ventura Capital operating London-Dubai-Tokyo w/backing from Aviva ventures Horizon ventures + other loyal funders Also completed Gates Foundation previously announced £6·5M commitment too.
This cash goes toward further work enhancing Owlstone’s Breath Biopsy® platform meanwhile developing new diagnostic tests / point-of-care devices readying them for market launch soon.
A recent announcement showed Owlstone teaming up w/three major U. S institutions launching multimillion-dollar campaign aiming early cancer detection/prevention The only UK member on ARPA-H’s POSEIDON project they’re set receive up-to nearly fifty million dollars working on OTC home-use cancer screening kits engineered best-in-class – quite exciting stuff!
An extension funding round pushed Enhanced Genomics total series A tally beyond nineteen mil backed mainly thru BGF Parkwalk Meltwind aiming expand internal pipeline targeting common conditions incl autoimmune illnesses like inflammatory bowel disease.
The latest rounds capped off Mission Therapeutics pulling down roughly thirteen point three mil pushing MTX325 lead drug candidate thru Phase Ib Parkinson proof-of-mechanism trials while Cyclana Bio landed £5M pre-seed backing pioneering novel tissue-level approaches focused women’s health care innovation…
This June saw Sortera Bio fundraising reaching seven-and-a-half mil pounds pre-seed financed primarily via CIC also bringing Astra Zeneca + Bio NTech onboard supporting efforts establishing deep screening platform collecting massive sequence/function data sets across millions biologic samples..
The core tech originated / validated @ Medical Research Council Laboratory Molecular Biology backed partially via Astra Zeneca Blue Sky Collaboration between LMB-AZ teams…
Iggnota Labs finished Feb closing just under seven mil seed funding co-led Montage ventures + Aix ventures USA supported Modi ventures Blue Wire capital Gaingels applying deep learning chemistry bioinformatics combined unlocking previously abandoned drug assets toxicity issue resolution promising fresh therapeutic opportunities..
Total Cambridge tech investment swelled past nine hundred nineteen mil thanks mostly Quantinuum six-hundred-million-dollar deal valuation topping ten billion dollars pre-money equity September..
This pile will power rapid scale-up quantum computing innovations prepping Helios launch expected soon along fault tolerant universal quantum computation breakthroughs striving achieve firsts globally..
Cusp AI snagged attention raising north hundred mil dollars+ during series A spearheaded NEA Temasek adding Nvidia Samsung Hyundai backing notable angel investors including Open AI co-founder Durk Kingma Dropbox Hugging Face founders etc building AI materials search engine speeding discovery processes dramatically..
Luminance topped February list getting seventy-five million during Series C progressing Legal-Grade™ AI applications funded Point72 Private Investments Forestay RPS Schroders capital March capital National Grid partners Slaughter May amongst others..
Difficult times hit Paragraf nearly ran dry waiting government clearance UAE Mubadala sovereign wealth contribution but eventually closed fifty-five-million-dollar fundraising advancing graphene chip products expanding manufacturing capacity scaling markets electronics energy medical device sectors alike..
Addition University spinouts CGD Nyobolt reported key closes CGD gallium nitride power electronics gained thirty-two-mil February growth funds led unnamed strategic partner boosted British patient capital Parkwalk advisors BGF CIC IQ capitals continuing support partnership usual suspects.. Nyobolt captured one-fifty-mil contract orders plus additional thirty-mil investments April IQ latitude Scania Takasago fueling ultrafast battery charging tech expansion powering demanding data centres globally…
Three promising early-stage startups stood out: Trismik Hiverge Common AI. Trismik spun out Cambridge Uni grabbed two-point-two-mil pounds aiding adaptive testing revolution slashing test-to-insight timeframes dramatically..
Hiverge founded ex-Google Deep Mind experts closed five-mil seed Sept enabling algorithm factory concept Flying Fish Seattle leads backed Ahren Google Deep Mind chief scientist Jeff Dean innovating program synthesis code generation radically..
Sir Andy Hopper famed Cambridgian plays central role Anthemis CAIVPCollaboration launching Common AI engineering/computing platform promoting AI startups enterprise academia investing across UK Europe widely..
Recent takeovers within cluster included Treatt selling natural extracts unit UK peer Natara Global fetched nearly one seventy-four mil pounds after market turbulence..
Ieso Digital Health divested telecare branch Mindler Sweden undisclosed sums combined platforms generating unmatched digital mental healthcare offerings NHS employ insurers public bodies access twenty-million adults currently..
Congenica snapped up French Seq One maintaining base Wellcome Sanger Institute birthplace becoming largest software-focused genomics provider globally serving 160+ labs across 30 countries terms undisclosed..
Go. Compare acquired Rnwl insurance innovator upfront three mil pounds potentially growing sixty-three mil pounds payments over five years founder Goncalo de Vasconcelos attracted crowdfund substantial backing including Simon Thorpe William Russell Jonathan Milner Sunil Shah…
Recur Software USA bought Cognidox who provide e QMS software vital life sciences medtech planning staff expansion post-acquisition terms confidential…
Johnson Matthey sold catalyst business division biggest deal cluster achieved selling non-core segment Honeywell International paying cash-debt-free two-point-four-billion-dollars (£1·8 bn) allowing JM focus clean air PGMs boosting shareholder returns sustainably…
On acquisitions made BY cam bridge companies Astra Zeneca picked Belgium-based Eso Biotec shelling four hundred twenty-five mill upfront potentially more depending milestones pioneering cell therapies showing encouraging results clinically…
Life science deals saw Germany Molab. ai acquired by Cresset Group whilst Source Bioscience took over local Clinical Labs both financials secret…
July Darktrace paid unknown amount acquiring Mira Security Pennsylvania strengthening network visibility decrypt traffic regulated sectors fuelling next-gen cyber defense tools…
Grant Instruments full buy Eltek Limited developers cloud environmental monitoring logging systems base Cambridge expanding scientific data acquisition portfolio…
Goodfellow landmark weeks acquiring Bureau Analysed Samples UK Suisse Technology Partners Switzerland gaining access top labs certified reference material facilities hint pipeline buys pending announcements…
June SDI Group continued spree picking Severn Thermal Solutions Ltd full ownership eight-point-three-two-million-pounds heating furnace environmental chamber makers supporting high-tech material processing/testing science fields product lines spanning healthcare aerospace astronomy motorsport water treatment art conservation areas…
Source link
